A Phase 2 interventional study of TTP435 and Placebo in Obesity, sponsored by vTv Therapeutics. Completed at 12 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-06-27.
Sponsored by vTv Therapeutics · Phase 2, Interventional, and Treatment
Multiple pathways including peripheral and central hormones and neurotransmitters are involved in the regulation of food intake and body weight. One of the most studied pathways involves the melanocortin receptor. Agouti-related protein (AgRP) and alpha-melanocyte stimulating hormone (alphaMSH)have been shown to play an integral role in food intake and body weight.
It is reasonable to speculate that if there is an imbalance of alphaMSH and AgRP exist in obese individuals and inhibiting the activity of AgRP may be of therapeutic benefit in treating obesity.
6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.
This study's enrollment of 100 is above the median of 78 across 4,878 interventional studies indexed under Obesity.
Browse Obesity studies →vTv Therapeutics is the lead sponsor of 14 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Placebo
Drug: TTP435
Participant Adverse Events
Time frame: Day 1 to Day 70 (2 weeks post dose)
Change from Baseline Glucose Levels
Time frame: Day 1 to Day 70 (2 weeks post dose)
Absolute Change in Body Weight
Time frame: Day 1 to Day 70 (2 weeks post dose)
Absolute Change in Body Mass Index
Time frame: Day 1 to Day 70 (2 weeks post dose)
Percent Change in Body Weight After 8 Weeks of Treatment with TTP435 or Placebo
Time frame: Day 1 to Day 70 (2 weeks post dose)
Effect Subject-reported Satiety
Time frame: Day 1 to Day 70 (2 weeks post dose)
Change from Baseline Insulin Levels
Time frame: Day 1 to Day 70 (2 weeks post dose)
Change from Baseline Free Fatty Acid Levels
Time frame: Day 1 to Day 70 (2 weeks post dose)
Change from Baseline Leptin Levels
Time frame: Day 1 to Day 70 (2 weeks post dose)
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
vTv Therapeutics